3 High-Flying Stocks That Could Soar Even More in 2025
And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...
2minutemedicine.com6d
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
Verona Pharma stock soars to all-time high of $51.88
In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...
Investing14d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
The bullish stance is based on the potential of Verona Pharma's Ohtuvayre™, which is expected to address a substantial total addressable market (TAM) of approximately 8.6 million symptomatic patients ...
FiercePharma16d
Breaking down the 55 new drug approvals of 2024
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...
Business Insider16d
Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
The company’s flagship product, Ohtuvayre, has a unique mechanism that combines bronchodilation and anti-inflammation for COPD treatment, potentially addressing unmet medical needs in a market ...
Investing17d
Verona Pharma stock target increased, keeps buy on Q4 sales
Looking beyond the current success of Ohtuvayre's launch, Truist Securities is also anticipating updates throughout 2025 regarding Verona Pharma's pipeline. These updates are expected to include ...